Clinical Trials Directory

Trials / Completed

CompletedNCT01883466

Health Effects of Biodiesel Exhaust Exposure

Cardiovascular Effects of Exposure to 100% Biodiesel Exhaust in Man

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
19 (actual)
Sponsor
Umeå University · Academic / Other
Sex
Male
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

Urban air pollution is a major contributor to greenhouse gases and has been shown to increase cardiovascular mortality and morbidity. This century has seen a rebirth of biofuel marketing and research, with biodiesel emerging as one of the strongest contenders within international markets. The pursuit of alternative renewable fuels is incredibly complex and has powered research in agriculture, biotechnology, production, transportation, feedstocks, ecology and biomass manufacturing. In spite of this, health effects have been an almost completely overlooked aspect. The purpose of this study is to investigate whether 100% biodiesel exhaust exposure in healthy volunteers leads to cardiovascular and inflammatory responses. Further investigations into the chemical composition of biodiesel exhaust will also be performed.

Conditions

Interventions

TypeNameDescription
OTHERForearm venous occlusion plethysmography studyMeasurement of forearm blood flow during unilateral intrabrachial infusion of four vasodilator drugs in incremental doses separated with 20-min washout periods. Bradykinin (endothelial-dependent vasodilator that releases t-PA) was infused at 100, 300 and 1000 pmol/min; acetylcholine (endothelial independent vasodilator that does not release t-PA) was infused at 5, 10 and 20 mcg/min; sodium nitroprusside (endothelial independent vasodilator that does not release t-PA) was infused at 2, 4 and 8 mcg/min and verapamil (endothelial independent and NO independent vasodilator that does not release t-PA) was infused at 10, 30 and 100 mcg/min. Bradykinin, acetylcholine and sodium nitroprusside were given in random order and verapamil was administered last due to its long acting effects.

Timeline

Start date
2012-09-01
Primary completion
2013-01-01
Completion
2013-04-01
First posted
2013-06-21
Last updated
2013-06-21

Locations

1 site across 1 country: Sweden

Source: ClinicalTrials.gov record NCT01883466. Inclusion in this directory is not an endorsement.